Indications and Purposes
| 1 Indications And Usage Vizimpro Is Indicated For The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (Nsclc) With Epidermal Growth Factor Receptor (Egfr) Exon 19 Deletion Or Exon 21 L858r Substitution Mutations As Detected By An Fda-Approved Test [See Dosage And Administration (2.1) ] . Vizimpro Is A Kinase Inhibitor Indicated For The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (Nsclc) With Epidermal Growth Factor Receptor (Egfr) Exon 19 Deletion Or Exon 21 L858r Substitution Mutations As Detected By An Fda-Approved Test. ( 1 ) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Dacomitinib |
|
ZINC72266312 |